NCT07426757

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

An Open-Label Phase 1 Study to Evaluate PF-07994525 in Participants With Advanced Malignancies

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.

Conditions

• Advanced Malignancies
• Advanced Cancer

Interventions

Type	Name	Description
DRUG	PF-07994525	Oral administration
DRUG	Midazolam	Oral administration

Timeline

• Start date: 2026-03-26
• Primary completion: 2029-07-08
• Completion: 2030-07-08
• First posted: 2026-02-23
• Last updated: 2026-04-07

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study